Overview
AI-powered digital pathology platform with FDA-authorized prostate cancer detection software.
Details
In 2021 the FDA authorized Paige Prostate, the first AI-based software designed to identify areas of interest on prostate biopsy images. Its platform supports prostate, breast, and colorectal cancer detection plus an AI foundation model for pathology research. Tempus AI acquired Paige in 2025.